Bachem

Bachem, established in 1971, is a premier global specialist in the development and manufacturing of peptides and oligonucleotides. Headquartered in Bubendorf, Switzerland, the company serves the pharmaceutical and biotechnology sectors with advanced solutions for drug discovery, development, and production. Bachem provides comprehensive services, from early-stage research and development through clinical trials to full-scale commercial manufacturing of complex active pharmaceutical ingredients (APIs). Its expertise spans solid-phase and liquid-phase peptide synthesis, alongside robust oligonucleotide manufacturing capabilities crucial for the burgeoning field of genetic medicines and RNA therapeutics.

Operating across 8 locations with an employee range of 1,000-5,000 individuals, Bachem maintains state-of-the-art production facilities globally. These facilities adhere to stringent quality standards and regulatory compliance, essential for meeting the demands of international pharmaceutical markets. The company's commitment to innovation is reflected in its advanced technology platforms and flexible manufacturing capabilities. To learn more about the expertise driving these operations, Meet Bachem's team. Bachem's deep scientific knowledge and decades of experience enable it to accelerate the journey from novel peptide discovery to marketed drugs, supporting therapeutic advancements across various disease areas.

With a reported revenue of $861.7M, Bachem demonstrates significant financial strength and market presence. This financial stability is further bolstered by a substantial share placement of $633.7 million in 2021, fueling continued growth and innovation. The company serves a diverse clientele, from emerging biotech startups to established multinational pharmaceutical corporations, positioning itself as a critical partner in the pharmaceutical supply chain. For detailed financial performance and investment insights, Explore financial highlights. Bachem's dedication to quality,View more...